HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Modification of serum uric acid concentration under long-term therapy with the lipid-regulating drug Duolip].

Abstract
During an 8-months treatment period the effect of Duolip on serum uric acid in 112 patients with hyperlipidemia was studied. In this open clinical trial a long-lasting hypouricemic effect could be shown for Duolip. This response was more pronounced with higher initial serum uric acid concentrations and could only be observed in patients with serum uric acid levels above 6.4 mg%. Thus, in one patient both risk factors of atherosclerosis--hyperlipidemia and hyperuricemia--can be treated by a single drug.
AuthorsR Scherhag
JournalFortschritte der Medizin (Fortschr Med) Vol. 101 Issue 36 Pg. 1635-7 (Sep 22 1983) ISSN: 0015-8178 [Print] Germany
Vernacular TitleBeeinflussung der Serumharnsäure-Konzentration unter Langzeittherapie mit dem Lipidregulans Duolip.
PMID6629296 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Hypolipidemic Agents
  • etofylline clofibrate
  • Uric Acid
  • Clofibrate
Topics
  • Clofibrate (analogs & derivatives, pharmacology, therapeutic use)
  • Humans
  • Hyperlipidemias (drug therapy)
  • Hypolipidemic Agents (pharmacology, therapeutic use)
  • Time Factors
  • Uric Acid (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: